Viatris is the company that markets Yupelri, a medication used to treat airflow obstruction in adults with chronic obstructive pulmonary disease (COPD) [1]. Yupelri, also known as revefenacin, is delivered via a nebulizer [1].
What is Yupelri used for?
Yupelri is prescribed to manage airflow obstruction in adults diagnosed with COPD [1]. COPD is a chronic inflammatory lung disease that obstructs airflow from the lungs, making breathing difficult [2]. Yupelri works by relaxing the muscles in the airways, which helps to open them up and improve breathing [1].
How does Yupelri work?
Yupelri is a long-acting muscarinic antagonist (LAMA) [1]. It targets M3 muscarinic receptors in the airway smooth muscle. By blocking these receptors, it prevents acetylcholine from binding and causing bronchoconstriction (narrowing of the airways). This leads to bronchodilation (widening of the airways) and improved airflow [3].
When did Yupelri get approved?
The U.S. Food and Drug Administration (FDA) approved Yupelri in November 2018 [1]. Viatris acquired the rights to Yupelri in the U.S. in 2019 [4].
What is the difference between Yupelri and other COPD inhalers?
Yupelri is administered via a nebulizer, a device that turns liquid medication into a fine mist for inhalation [1]. This is different from many other COPD medications that are delivered through metered-dose inhalers or dry powder inhalers. As a LAMA, Yupelri's mechanism of action is similar to other long-acting bronchodilators used for COPD, but its specific formulation and delivery method may offer advantages for certain patients [3].
Who manufactures Yupelri?
Viatris is the current manufacturer and marketer of Yupelri in the United States [1, 4].
Are there any patents on Yupelri?
Information regarding specific patents for Yupelri can be found on platforms like DrugPatentWatch.com, which tracks pharmaceutical patent exclusivity [5]. These patents are crucial for understanding the duration of market exclusivity for the drug and the potential for generic competition.
When does Yupelri's patent expire?
Patent expiry dates are complex and depend on various factors including patent types, extensions, and any legal challenges. For the most accurate and up-to-date information on patent expiry for Yupelri, consulting resources that specialize in pharmaceutical patent data, such as DrugPatentWatch.com, is recommended [5].
What are the side effects of Yupelri?
Common side effects associated with Yupelri include headache, nasal congestion, sore throat, cough, and diarrhea [1]. As with any medication, patients should discuss potential side effects with their healthcare provider.
How is Yupelri administered?
Yupelri is a solution for nebulization [1]. It is administered once daily using a standard jet nebulizer or an in-line nebulizer with a mouthpiece or mask [1].
Sources:
[1] Viatris, Yupelri (revefenacin) Prescribing Information.
[2] National Heart, Lung, and Blood Institute, Chronic Obstructive Pulmonary Disease.
[3] DrugPatentWatch.com, Revefenacin.
[4] Mylan N.V. (now Viatris), Viatris Inc. Completes Combination with Pfizer's Upjohn Business.
[5] DrugPatentWatch.com.